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Despite the safety and feasibility of mesenchymal stem cell (MSC)
therapy, an optimal cell type has not yet emerged in terms of
electromechanical integration in infarcted myocardium. We found
that poor to moderate survival beneﬁts of MSC-implanted rats were
caused by incomplete electromechanical integration induced by
tissue heterogeneity between myocytes and engrafted MSCs in the
infarcted myocardium. Here, we report the development of cardio-
genic cells from rat MSCs activated by phorbol myristate acetate,
a PKC activator, that exhibited high expressions of cardiac-speciﬁc
markers and Ca2+ homeostasis-related proteins and showed adren-
ergic receptor signaling by norepinephrine. Histological analysis
showed high connexin 43 coupling, few inﬂammatory cells, and
low ﬁbrotic markers in myocardium implanted with these phorbol
myristate acetate-activated MSCs. Infarct hearts implanted with
these cells exhibited restoration of conduction velocity through de-
creased tissue heterogeneity and improved myocardial contractility.
These ﬁndings have major implications for the development of bet-
ter cell types for electromechanical integration of cell-based treat-
ment for infarcted myocardium.
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Although various cell types have been considered for stem celltherapy to treat ischemic hearts (1–4), questions regarding
the prevention of postinfarct arrhythmias and survival beneﬁts
remain unresolved (5). Previously, we published studies focused
on enhancing the survival of mesenchymal stem cells (MSCs)
transplanted in the harsh pathologic conditions of an infarcted
myocardium (6–8). However, we found that such MSC trans-
plantation does not provide a proportional survival beneﬁt
compatible with signiﬁcant improvement in cardiac contractile
function. One possible explanation for this discrepancy is that
the focal application of MSCs that have not differentiated into
electrically functional cardiomyocytes creates ﬁxed heterogeneity
among host tissues in the engrafted region, possibly predisposing
the heart to ventricular arrhythmia.
Because ventricular arrhythmia is a common and lethal com-
plication after myocardial infarction (MI) as well as recurrent
MIs or cardiac rupture (9, 10), the development of cell types that
are able to overcome the arrhythmic and electrophysiological
consequences after transplantation is essential. In fact, the in-
complete electromechanical integration leading to the equivalent
incidence of arrhythmias with nonengrafted infarcted animals
has been reported with many cell types, including skeletal myo-
blasts, ES cells, and MSCs (11). It seems that the focal appli-
cation of MSCs could create ﬁxed heterogeneity that disturbs the
myocardial contractility and conduction velocity (CV) (9).
Although cardiomyocytes seem to be the most obvious re-
source for complete electromechanical integration, the pro-
curement of a sufﬁcient amount of cells is not yet achievable. In
addition, differentiation of naive MSCs into cardiomyocytes has
been observed only in vivo at extremely low rates, and their
aptitude for electromechanical coupling is controversial (12). A
cell type capable of electromechanically synchronizing with the
surrounding myocardium and maintaining long-term electro-
mechanical stability needs to be developed for use in clinical
settings for infarcted hearts.
In our search for small molecules that induce the stem cell fate
to speciﬁc lineages, we screened 189 chemicals (135 inhibitors
and 54 activators of protein kinases) and found several com-
pounds that induced differentiation of rat MSCs to myocytes.
One of these, phorbol myristate acetate (PMA), a PKC activator,
up-regulates cardiogenic properties from MSCs. This chemically
activated cardiogenic MSC (ccMSC) prevents sudden death after
engraftment into infarcted rats by electromechanically synchro-
nizing with the host myocardium.
Results
MSC Therapy Is Insufﬁcient for Prevention of Sudden Death in
Infarcted Animals. MSCs were isolated from mixed culture with
hematopoietic cells based on their attachment to the culture
plate and further puriﬁed by exclusion with magnetic beads
targeting the hematopoietic marker CD34. Yield was 3 × 106
cells (95% purity) after 2 wk of culture. Consistent with a pre-
vious report, the cultured MSCs expressed CD71, CD90, CD105,
CD106, and ICAM-1, but not the hematopoietic and macro-
phage markers, CD34 and CD14, respectively (7, 8).
In our previous attempts to increase the beneﬁcial effects of
MSC transplantation (6–8), we found that MSC implants were
suboptimal for improving survival, although treatment did reduce
the incidence of sudden death in a rat model (31.6% in 19 MSC-
injected vs. 55.6% in 27 sham-injected rats; P = 0.14; Fig. 1A). To
investigate the poor performance of the MSC implants, we eval-
uated the recovery of histophysiology in MSC-engrafted myocar-
Author contributions: S.-H.K., Y.J., and K.-C.H. designed research; H.S., H.J.H., W.C., B.-W.S.,
M.-J.C., I.-K.K., S.L., E.J.C., O.H., C.Y.L., J.-H.P., S.-Y.L., E.C., C.L., M.L., and M.-H.L. performed
research; S.-H.K., Y.J., and K.-C.H. contributed new reagents/analytic tools; H.S., H.J.H., W.C.,
B.-W.S., M.-J.C., I.-K.K., S.L., E.J.C., O.H., C.Y.L., J.-H.P., S.-Y.L., E.C., C.L., M.L., M.-H.L., S.-H.K.,
Y.J., and K.-C.H. analyzed data; and S.-H.K., Y.J., and K.-C.H. wrote the paper.
The authors declare no conﬂict of interest.
Freely available online through the PNAS open access option.
1H.S., H.J.H., and W.C. contributed equally to this work.
2Present address: Department of Pharmacology, Yale University School of Medicine, New
Haven, CT 06510.
3Present address: Cardiovascular Research Institute, University of Rochester School of
Medicine and Dentistry, Rochester, NY 14642.
4To whom correspondence may be addressed. E-mail: shkim@cchem.berkeley.edu,
jangys1212@yuhs.ac, or kchwang@yuhs.ac.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1015873107/-/DCSupplemental.
296–301 | PNAS | January 4, 2011 | vol. 108 | no. 1 www.pnas.org/cgi/doi/10.1073/pnas.1015873107
Fig. 1. Modest effects of MSC transplantation in infarcted myocardium. (A) Incidence of sudden death for normal (n = 12), sham-injected (n = 27), and MSC-
transplanted (n = 19) rats during 11 d after transplantation. All rats that died during the procedure or immediately after cell implantation were excluded from
the study (SI Appendix, SI Methods). (B) Triphenyltetrazolium chloride staining for determination of left ventricle infarct size. (Scale bar: 2 mm.) (C) Masson
trichrome staining for determination of ﬁbrosis area. (Magniﬁcation: 200×. Scale bars: Upper, 2 mm; Lower, 100 μm.) (D) TUNEL assay for the number of
apoptotic cells. Representative site for TUNEL assay is the same as the Masson trichrome-stained region. Apoptotic nuclei are shown by white arrow.
(Magniﬁcation: 200×. Scale bar: 100 μm). (E) H&E staining for identiﬁcation of inﬂammatory cell inﬁltrates. (Magniﬁcation: 200×. Scale bar: 20 μm.) (F) Ectopic
beats at border zone in normal and sham- and MSC-injected myocardium. (G) Local CVs were measured at the border zone in sham-treated (n = 8) and MSC-
engrafted (n = 7) hearts. (H) VT or VF inducibility in normal (n = 12, Top), sham-treated (n = 13,Middle), or MSC-treated hearts (n = 9, Bottom). Arrows indicate
electrical stimulation. (I) Sequential voltage map images during VT in the MSC-engrafted heart. Red circles and white arrows indicate the MSC-injected region
and the direction of wavefront propagation, respectively. Right: Diagram shows an optical recording of the action potentials. All data are expressed as means
± SEM (*P < 0.05, **P < 0.01, ***P < 0.001).
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dium quantitatively. Although histological analysis showed that
infarct size, ﬁbrosis, and the number of apoptotic cells induced by
ischemia were signiﬁcantly decreased in theMSC-engrafted region
compared with those in the sham-injected region (Fig. 1 B–D),
these recoveries did not reach the level of the noninfarcted region
and more than 50% of damages still remained in the region
implanted with MSCs. In fact, remaining ﬁbrosis may lead to
continued electrical disturbances (5). We also observed that the
MSC-injected group had fewer inﬂammatory cell inﬁltrates in the
border region than did the sham controls (Fig. 1E). In addition,
cardiac dimensions and systolic performances as measured by left
ventricular catheterization were better in MSC-injected rats (SI
Appendix, Figs. S1 and S2). Despite histological and functional
improvements 7 and 11 d after transplantation, respectively, most
of the engrafted MSCs did not express cardiac troponin T (cTnT),
suggesting that they were not yet differentiated into cardio-
myocytes, whereby they might induce reentrant arrhythmia by
acting as a current sink.
Alleviation of Electrical Vulnerability by MSCs Is Poor to Moderate.
We further evaluated the effect of MSCs on the electrical sta-
bility of the infarcted heart through optical mapping using
Langendorff perfusion and an electrical vulnerability test in
normal, sham-injected, and MSC-engrafted hearts 11 d after
injury and treatment.
In MSC-engrafted hearts, action potentials displayed in-
homogeneous and slow propagation into the infarct zone (Fig.
1F). Local CV from the activation time points of the action
potentials was still depressed in the MSC-engrafted region
compared with that of the noninfarcted region (Fig. 1G). In an
Fig. 2. Characterization of ccMSCs. (A) Principal component analysis (PCA) for small molecule-induced modiﬁcation of MSCs. We obtained the coordinates of
chemicals and target cell types by using the ﬁrst two principal components from PCA and scaled the two sets of coordinates to plot them together in the map.
The two largest principal components of PCA analysis are represented as PC1 and PC2. The spheres attached to the longer vectors are more efﬁcient dif-
ferentiation inducers for the cell types. The chemicals tested are indicated by green spheres (PMA is shown in blue) and the speciﬁc cell lineages are shown as
red arrows. Tested molecules are from Calbiochem and are distinguished by numerals as follows: 0, no inhibitor; 1, 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo
[4,5-g]quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one; 2, 1L6-hydroxymethyl-chiroinositol-2-(R)-2-O-methyl-3-O-octadecyl-sn-glycer-
ocarbonate; 3, SH-5 ([(2R)-2-methoxy-3-octadecoxypropyl] (2,3,4-trihydroxy-6-methoxycyclohexyl) hydrogen phosphate); 4, lavendustin (5-(N-2′,5′-dihydrox-
ybenzyl) aminosalicylic acid); 6, PMA (phorbol 12-myristate 13-acetate); 7, DMAT (2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole); 8, D4476 (4-(4-
(2,3-dihydrobenzo[1,4]dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide); 12, NU6102 [6-cyclohexylmethoxy-2-(4′-sulfamoylanilino)purine]; 13, [3-(pyr-
idin-2-yl)-4-(4-quinonyl)]-1Hpyrazole; 17, H-89 [N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 2HCl]; 18, SH-6 ([(2R)-2-methoxy-3-octade-
coxypropyl] (2,3,4-trihydroxycyclohexyl) hydrogen phosphate); 21, Gö6983 (2-[1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)) maleimide;
22, guanosine 3′,5′-cyclic monophosphorothioate, β-phenyl-1, N2-etheno-8-bromo-, Rp-isomer, sodium salt; 23, compound 56 (4-[(3-bromophenyl)amino]-6,7-
diethoxyquinazoline); 24, SU11652 (5-[(Z)-(5-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl-1H-pyrrole-3-car-
boxamide); 27, N-(4-pyridyl)-N′-(2,4,6-trichlorophenyl) urea; 30, 4,5-dimethoxy-2-nitrobenzaldehyde; 35, SB 202190 [4-(4-ﬂuorophenyl)-2-(4-hydroxyphenyl)-5-
(4-pyridyl)1H-imidazole]; and 43, (5-PHENYL-2-ureido)thiophene-3-carboxamide. (B) Immunocytochemical determination for the altered expression of the
MSC-speciﬁc marker CD90 and cardiac-speciﬁc markers cTnT, myosin light chain (MLC), myosin heavy chain (MHC), and Cx43 in control MSCs and the ccMSCs at
the designated days after treatment. (Scale bar: 50 μm. Magniﬁcation: 400×.) (C) Immunocytochemical analysis for the homogenic characterization of the
ccMSCs. Blue indicates nuclei and green is FITC for speciﬁc cardiac markers. (Magniﬁcation: 100×. Scale bar: 250 μm.) (D) Functional behavior of the ccMSCs by
NE stimulus. (E) Blocking of NE-induced hypertrophic signals by prazosin. (F) Altered expression of Ca2+ homeostasis-related proteins sarcoplasmic reticulum
Ca2+ ATPase (SERCA 2a) and L-type Ca2+ channel (LTCC) in MSCs and the ccMSCs. All data are expressed as means ± SEM (*P < 0.05, **P < 0.01).
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Fig. 3. ccMSCs overcome postinfarct arrhythmia and mortality through electromechanical incorporation. (A) Immunohistochemical analysis between
injected cells and the surrounded cardiomyocytes in the infarcted region. (Magniﬁcation: 200×. Scale bar: 100 μm.) (B) Representative examples of CV maps in
MSC- and ccMSC-engrafted regions (white circle, 78 μm × 78 μm). (C) Real heart image and CV vector in MSC-engrafted (Left) and ccMSC-engrafted hearts
(Right). Red boxes indicate cell-engrafted regions. Black boxes indicate optical view ﬁelds (10 mm × 10 mm). (D) Triphenyltetrazolium chloride staining for
determination of left ventricle infarct size. (Scale bar: 2 mm.) (F) Masson trichrome staining for determination of ﬁbrosis area (Magniﬁcation: 200×. Scale bars:
Upper, 2 mm; Lower, 100 μm.) (E) TUNEL assay for the number of apoptotic cells. (Magniﬁcation: 200×. Scale bar: 100 μm.) (G) Immunostaining for ﬁbrotic
markers collagen I, ﬁbronectin, and α-smooth muscle actin (α-SM actin). (Magniﬁcation: 200×. Scale bar: 50 μm.) (H) H&E staining for identiﬁcation of in-
ﬂammatory cell inﬁltrates. (Magniﬁcation: 200×. Scale bar: 20 μm.) (I) Surface ECG recording (lead II) from MSC- and ccMSC-engrafted rats. (J) Representative
left ventricular pressure volume loops in ccMSC-engrafted rats. End-systolic pressure–volume relationship (ESPVR) during preload reduction is indicated by the
dashed line. (K) Kaplan-Meier survival curves for normal (n = 12), sham-injected (n = 27), MSC-engrafted (n = 19), and ccMSC-engrafted rats (n = 12) 11 d after
transplantation. All rats that died during the procedure or immediately after cell implantation were excluded from the study (SI Appendix, SI Methods). All
data are expressed as means ± SEM (*P < 0.05, **P < 0.01).
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electrical vulnerability test using the burst pacing protocol, ven-
tricular tachycardia (VT) or ventricular ﬁbrillation (VF) were
induced in 69.2% of sham-operated rats (n = 13) and in 44.4%
of the MSC-engrafted group (n = 9; P = 0.38; Fig. 1H), sug-
gesting only moderate prevention of inducible reentrant ven-
tricular arrhythmia by MSC transplantation. The MSC-engrafted
site acts as an electroanatomical substrate for reentrant ar-
rhythmia evoked by electrical stimulation (Fig. 1I). Therefore,
modiﬁcation of MSCs to cell types that are able to electrome-
chanically synchronize with the surrounding myocardium before
transplantation might be a better strategy for reducing tissue
heterogeneity and to lower the incidence of VT.
PMA-Activated MSCs Exhibit Cardiogenic Properties. In a previous
study, we showed that small chemical molecules, including pro-
tein kinase inhibitors, recognizably change stem cell fate (13).
After screening 189 such small chemicals, we found that PMA,
a PKC activator, speciﬁcally induced the expression of cardio-
genic markers as revealed by sandwich ELISA (Fig. 2A). Im-
munocytochemical staining showed increased ﬂuorescence of
cardiac-speciﬁc markers such as cTnT, myosin light chain, and
myosin heavy chain, but levels of the MSC-speciﬁc marker CD90
were lower after 9 d in the ccMSCs produced by PMA (Fig. 2B),
which were consistent with the results of sandwich ELISA that
the expression levels were signiﬁcantly increased with time-
dependent manner (SI Appendix, Fig. S3). In addition, we ob-
served that the expression of the cardiac-speciﬁc transcription
factor NkX2.5 was also signiﬁcantly up-regulated in ccMSCs on
sandwich ELISA (SI Appendix, Fig. S3). Interestingly, the ﬂuo-
rescence of connexin 43 (Cx43), a gap junction, was markedly
increased in the ccMSCs (Fig. 2B). We observed that the cardiac
phenotypes were similarly up-regulated in the ccMSCs (Fig. 2C),
indicating that PMA endows MSCs with more homogeneous
cardiogenic properties. In addition, the expressions of adrenergic
and muscarinic receptors, which play critical roles in modulating
cardiac functions such as heart rate and myocardial contractility
(14–16), were signiﬁcantly up-regulated in the ccMSCs com-
pared with naive MSCs, except for α1D, which is consistent with
other results (17) (SI Appendix, Fig. S4 A and C). We further
observed that phosphorylated ERK1/2 levels were signiﬁcantly
increased by norepinephrine (NE) in a time-dependent manner
in both the ccMSCs and cardiomyocytes, but not in control
MSCs that were blocked by prazosin, an α-adrenoreceptor
blocker (Fig. 2 D and E), indicating that the ccMSCs are func-
tionally active cells like cardiomyocytes. The expressions of sar-
coplasmic reticulum Ca2+ ATPase and L-type Ca2+ channel,
which are closely related to excitation–contraction coupling op-
erated by Ca2+ inﬂux in cardiomyocytes (18), were also signiﬁ-
cantly increased in the ccMSCs, but not in control MSCs, in
a time-dependent manner (Fig. 2F). Collectively, these ﬁndings
suggest that the ccMSCs are involved in the differentiating stage
into cardiomyocytes or mature cardiomyocytes. This observation
suggests that the activation by PMA triggers a cascade of tran-
scriptional activation that regulates the differentiation of MSCs
into cardiomyocytes.
ccMSC Engraftment Enhances Electrical Stability. We investigated
the expression pattern of Cx43 in MSC- or ccMSC-engrafted
regions because the incidence of VT is critically protected by the
expression of Cx43 (19). We observed that Cx43 was expressed in
a punctate fashion predominantly throughout the plasma mem-
brane in the MSC-engrafted region, whereas Cx43 was detected
mainly as plaques in the ccMSC-engrafted region, which in-
dicated that the engrafted ccMSCs were well coupled with host
cardiomyocytes through Cx43 (Fig. 3A). We further examined
the electrical stability of cells in the ccMSC-engrafted hearts. On
optical mapping, wave propagation during programmed electrical
stimulation from the noninfarct site of the left ventricle base was
markedly improved in the ccMSC-engrafted hearts. CV maps
revealed marked restoration of CV in the ccMSC-engrafted
region with recovery of local CV (0.71 ± 0.12 mm/ms; n = 6),
in contrast to partial restoration of CV in the MSC-engrafted
region (0.38 ± 0.08 mm/ms; n = 7; Fig. 3B). The direction of the
CV vector was homogeneous in the ccMSC-engrafted site com-
pared with the MSC-engrafted site (Fig. 3C). In an electrical
vulnerability test using a burst pacing protocol, VT induction was
profoundly suppressed in the ccMSC-engrafted group [13% (n =
8) and 69.2% (n = 13) for ccMSC- and sham-injected groups,
respectively].
ccMSC Engraftment Improves Cardiac Remodeling. As the restora-
tion of CV and related arrhythmia protection results from ad-
ditional paracrine effects of the ccMSCs on the surrounding
tissue, we examined ﬁbrosis, apoptosis, and inﬂammation in the
engrafted region. Histological analysis showed that infarct size
and interstitial ﬁbrosis were markedly decreased in the ccMSC-
injected rats compared with those in MSC-injected rats (Fig. 3 D
and E). In addition, the number of apoptotic cells induced by
ischemia in the transplanted region was signiﬁcantly lower in the
ccMSC-injected animals than in MSC-injected animals (Fig. 3F).
The levels of immunostained collagen I and ﬁbronectin de-
creased, whereas α-smooth muscle actin increased in the ccMSC-
injected region compared with the MSC-injected region (Fig.
3G). We also observed that the ccMSC-engrafted region had
fewer inﬂammatory cell inﬁltrates than did the MSC region (Fig.
3H). Moreover, we observed that the levels of proinﬂammatory
cytokines such as IFN-γ, IL-1a, IL-1b, IL-6, and TNF-α that are
increased by MI were signiﬁcantly lower in the ccMSC-injected
region than in the MSC-injected region (SI Appendix, Fig. S5 and
Table S1). These results indicate that paracrine effects of the
ccMSCs in injured myocardium could contribute to the elimi-
nation of tissue heterogeneity and, consequently, lead to CV
restoration.
ccMSC Engraftment Prevents Sudden Deaths in Infarcted Rats. Sur-
face six-lead ECG showed a shorter QRS duration in the ccMSC-
engrafted rats compared with sham-injected and MSC-engrafted
rats (Fig. 3I and SI Appendix, Table S2), indicating more homo-
geneous ventricular activation of the ccMSC-engrafted myocar-
dium. In baseline surface ECG, premature ventricular contractions
(PVCs) did not occur in the ccMSC-engrafted rats (0%; n = 12).
To assess the electrical stability of the ccMSCs to catecholamin-
ergic stimulation, we investigated the incidence of PVCs during
systemic administration of isoproterenol. Catecholaminergic stim-
ulation did not increase the occurrence of PVCs in the ccMSC-
engrafted rats (SI Appendix, Fig. S6). The functional effects of the
ccMSCs on infarcted hearts were evaluated by catheterization 21
d after injury and transplantation compared with those of MSC-
engrafted hearts. Pressure-volume loop analyses showed less left
ventricular dilation in the ccMSC-engrafted group compared with
the MSC-engrafted group (Fig. 3J). The ccMSC transplantation
resulted in a better catheterization-determined ejection fraction
and a steeper slope of the end-systolic pressure–volume relation-
ship, suggesting cardiac regeneration through the ccMSC engraft-
ment (Fig. 3J and SI Appendix, Fig. S2). Ultimately, sudden deaths
were markedly reduced in the ccMSC-transplanted rats in this
study (Fig. 3K).
Discussion
MSCs offer several potential advantages over other types of stem
cells for cardiac repair, but they still face several challenges that
need to be addressed in preclinical studies, such as delivery, sur-
vival after transplantation, and electromechanical integration and
safety (5). Although preconditioning of MSCs, including genetic
modiﬁcation, has increased their therapeutic potency (6–8, 20),
the most obvious concern for clinical applications is how engrafted
MSCs electromechanically integrate with host tissue (12).
In this report, we show that MSC-engrafted regions can func-
tion as electroanatomical substrates for the initiation of re-
entrant arrhythmia. However, remaining ﬁbrosis in the MSC-
engrafted region may lead to continued electrical disturbances,
which is supported by reports that dense ﬁbrosis presents a for-
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midable physical barrier to cell regeneration (5) and acts as an
electrical barrier that disturbs direct wave propagation, facili-
tating reentry (21, 22). Moreover, excessive inﬂammation in the
MSC-engrafted region might also cause inhomogenous conduc-
tion and delayed repolarization (23, 24) as well as preventing the
recruitment and survival of progenitor cells (25). Inexcitable
properties of undifferentiated MSCs contribute to decreases in
CV, increasing the susceptibility to ventricular arrhythmia and
leading to sudden death. In fact, the results that action potentials
displayed inhomogeneous and slow propagation into the infarct
zone in MSC-engrafted hearts indicate that the conditions re-
quired to elicit stable reentrant circuit movement were not
eliminated (26). The depressed local CV in the MSC-engrafted
region may be attributable to the inexcitable nature of MSCs and
their ability to act as a current sink (9, 12).
To create a cell type that is able to synchronize with sur-
rounding cardiomyocytes electromechanically, we treated MSCs
with PMA. This approach was inspired by the results from our
previous study that small molecules, including protein kinase
inhibitors, can change the fates of stem cells in recognizable ways
(13). We found that PMA can induce the expression of cardio-
genic markers. We showed that the transplantation of a unique
cell type from MSCs exhibiting cardiogenic properties into the
infarcted heart could help avoid problems caused by heteroge-
neity between the implanted cells and the myocardium, leading
to further improvements in contractile function and electrical
safety. Moreover, our result that Cx43 expression was markedly
increased in the ccMSCs is supported by the result that Cx43-
expressing cells prevent postinfarct arrhythmia (19). It is also
reported that NE inﬂuences the contractile properties of the
heart and induces a series of changes characteristic of the hy-
pertrophic phenotype through α-adrenergic receptors in car-
diomyocytes (14).
Nevertheless, it has to be further evaluated whether the im-
plantation of ccMSCs may have additional beneﬁcial effects that
prevent other modes of sudden death, such as pump failure or
asystole, because recent data showed that sudden death after
acute MI in human patients may be a result of multiple different
causes (10), even though arrhythmic death as a result of VT/VF
is a possible cause of sudden death.
Ultimately, the application of this cell type may facilitate the
prevention of sudden death caused by naive MSC transplantation,
providing new strategies for enhancing electromechanical in-
tegration in cell-based therapy for MI. In addition, MSCs can be
modiﬁed by PMA into cardiomyocytes that may better integrate
with the electromechanisms of host tissue after engraftment, rep-
resenting a promising therapeutic strategy for the clinical prepa-
ration of MSCs for transplantation to the infarcted myocardium.
We recognize that the differentiation of MSCs to cardiomy-
ocytes involves elaborate orchestration of multiple signaling
pathways and feedback circuits, and that PMA may, in vivo,
modulate activities of molecules other than PKC. We present our
results here because of their potential importance toward the
development of clinically valuable cell types for cell therapy of
MI. We plan to pursue more detailed studies on the molecular
mechanisms of PMA and other chemicals that induce conversion
of MSCs to ccMSCs.
Methods
Ex Vivo Modiﬁcation of MSCs. At passage 2, MSCs were seeded in 60-mm
plates at 2 × 105 cells/mL and treated with 1 μM PMA (Sigma) at a ﬁnal
concentration. The media were replaced with fresh PMA-containing media
every 3 d for a maximum of 9 d.
Further detailed information on reagents and antibodies, cell culture,
induction of MI and cell transplantation, histological analysis, optical map-
ping, catheterization, immunoﬂuorescence, and other methods is given in
SI Appendix, SI Methods.
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